Symbols / OMER
OMER Chart
About
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; zaltenibart that is in phase 3 clinical trials for Paroxysmal nocturnal hemoglobinuria; in phase 2 clinical trial for the treatment complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Immunostimulator Combination Therapies, and Oncotoxins and Immunomodulators for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 818.90M |
| Enterprise Value | 1.15B | Income | -121.24M | Sales | — |
| Book/sh | -3.15 | Cash/sh | 0.51 | Dividend Yield | — |
| Payout | 0.00% | Employees | 202 | IPO | — |
| P/E | — | Forward P/E | 23.73 | PEG | — |
| P/S | — | P/B | -3.67 | P/C | — |
| EV/EBITDA | -8.93 | EV/Sales | — | Quick Ratio | 0.53 |
| Current Ratio | 0.89 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -2.02 | EPS next Y | 0.49 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-31 | ROA | -32.41% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 70.90M |
| Shs Float | 68.23M | Short Float | 25.85% | Short Ratio | 6.51 |
| Short Interest | — | 52W High | 17.65 | 52W Low | 2.95 |
| Beta | 2.45 | Avg Volume | 2.41M | Volume | 864.69K |
| Target Price | $38.00 | Recom | Buy | Prev Close | $11.44 |
| Price | $11.55 | Change | 0.96% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$38.00
Mean price target
2. Current target
$11.55
Latest analyst target
3. DCF / Fair value
$-18.16
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$11.55
Low
$36.00
High
$40.00
Mean
$38.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-27 | main | D. Boral Capital | Buy → Buy | $36 |
| 2026-01-08 | main | HC Wainwright & Co. | Buy → Buy | $40 |
| 2026-01-08 | main | D. Boral Capital | Buy → Buy | $36 |
| 2025-12-24 | main | D. Boral Capital | Buy → Buy | $36 |
| 2025-12-01 | main | D. Boral Capital | Buy → Buy | $36 |
| 2025-11-14 | main | D. Boral Capital | Buy → Buy | $36 |
| 2025-10-16 | main | D. Boral Capital | Buy → Buy | $36 |
| 2025-10-15 | reit | Needham | Hold → Hold | — |
| 2025-10-15 | reit | WBB Securities | Strong Buy → Strong Buy | $45 |
| 2025-10-15 | main | HC Wainwright & Co. | Buy → Buy | $20 |
| 2025-10-15 | main | D. Boral Capital | Buy → Buy | $36 |
| 2025-09-03 | main | D. Boral Capital | Buy → Buy | $36 |
| 2025-08-15 | main | D. Boral Capital | Buy → Buy | $36 |
| 2025-08-15 | reit | Needham | Hold → Hold | — |
| 2025-07-25 | main | D. Boral Capital | Buy → Buy | $36 |
| 2025-06-30 | main | D. Boral Capital | Buy → Buy | $36 |
| 2025-06-10 | init | HC Wainwright & Co. | — → Buy | $9 |
| 2025-05-16 | reit | Needham | Hold → Hold | — |
| 2025-05-13 | main | D. Boral Capital | Buy → Buy | $36 |
| 2025-05-07 | main | D. Boral Capital | Buy → Buy | $36 |
- Omeros (OMER) Expected to Announce Earnings on Tuesday - MarketBeat ue, 24 Feb 2026 13
- Experimental Omeros AML drug wiped out tumors in animal tests - Stock Titan ue, 17 Feb 2026 13
- Can OMER stock retain Novo Nordisk driven gains over the long-term? - TradingView Wed, 15 Oct 2025 07
- Omeros stock rises in premarket after $36,000-a-vial Yartemlea price is set - TechStock² hu, 08 Jan 2026 08
- Omeros stock soars after $2.1 billion deal with Novo Nordisk - Investing.com Wed, 15 Oct 2025 07
- Omeros Corporation's (NASDAQ:OMER) market cap dropped US$60m last week; individual investors who hold 50% were hit as were institutions - Yahoo Finance Wed, 04 Feb 2026 08
- Omeros stock spikes on Novo licensing deal (OMER:NASDAQ) - Seeking Alpha Wed, 15 Oct 2025 07
- Omeros Stock Garners High Retail Attention Ahead Of FDA Verdict For Life-Saving Drug - Stocktwits Wed, 24 Dec 2025 08
- Omeros Corporation (NASDAQ:OMER) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat Sat, 21 Feb 2026 06
- FDA approves first treatment for often-fatal stem cell complication - Stock Titan Wed, 24 Dec 2025 08
- Omeros stock soars after FDA approves first treatment for TA-TMA - Investing.com Wed, 24 Dec 2025 08
- Omeros: Key Milestone Ahead, Risk-Averse Investors Should Avoid (NASDAQ:OMER) - Seeking Alpha Fri, 21 Nov 2025 08
- Omeros Corporation (OMER): Novo Nordisk Deal Creating Buzz - Yahoo Finance Wed, 10 Dec 2025 08
- Omeros (OMER) Stock Surges After Hours on Dec. 24, 2025 After FDA Approves Yartemlea — What to Know Before the Next Market Open - TechStock² Wed, 24 Dec 2025 08
- Omeros (NASDAQ:OMER) Stock Crosses Above Two Hundred Day Moving Average - Here's What Happened - MarketBeat Mon, 16 Feb 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 400000 | 4108000 | — | Conversion of Exercise of derivative security at price 10.27 per share. | DEMOPULOS GREGORY A. M.D. | Chief Executive Officer | — | 2026-02-18 00:00:00 | D |
| 1 | 60000 | 750915 | — | Sale at price 12.31 - 12.72 per share. | BORGES DAVID J. | Officer | — | 2026-01-13 00:00:00 | D |
| 2 | 30000 | 91800 | — | Conversion of Exercise of derivative security at price 3.06 per share. | BORGES DAVID J. | Officer | — | 2026-01-13 00:00:00 | D |
| 3 | 600000 | — | — | Stock Gift at price 0.00 per share. | DEMOPULOS GREGORY A. M.D. | Chief Executive Officer | — | 2025-10-13 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.01 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -157.00M | -147.27M | -158.38M | -170.49M |
| TotalUnusualItems | 0.00 | 4.11M | 0.00 | 0.00 |
| TotalUnusualItemsExcludingGoodwill | 0.00 | 4.11M | 0.00 | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -182.63M | -174.92M | -182.03M | -191.55M |
| ReconciledDepreciation | 950.00K | 920.00K | 952.00K | 1.39M |
| ReconciledCostOfRevenue | 0.00 | |||
| EBITDA | -157.00M | -143.16M | -158.38M | -170.49M |
| EBIT | -157.95M | -144.08M | -159.33M | -171.88M |
| NetInterestIncome | -13.37M | -14.50M | -18.64M | -17.93M |
| InterestExpense | 24.68M | 30.84M | 22.70M | 19.67M |
| InterestIncome | 11.30M | 16.34M | 4.06M | 1.74M |
| NormalizedIncome | -182.63M | -179.03M | -182.03M | -191.55M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -156.81M | -117.81M | 47.42M | 194.24M |
| TotalExpenses | 169.26M | 164.53M | 163.39M | 173.62M |
| TotalOperatingIncomeAsReported | -169.26M | -164.53M | -163.39M | -173.62M |
| DilutedAverageShares | 58.17M | 62.74M | 62.74M | 62.34M |
| BasicAverageShares | 58.17M | 62.74M | 62.74M | 62.34M |
| DilutedEPS | -2.70 | -1.88 | 0.76 | 3.12 |
| BasicEPS | -2.70 | -1.88 | 0.76 | 3.12 |
| DilutedNIAvailtoComStockholders | -156.81M | -117.81M | 47.42M | 194.24M |
| NetIncomeCommonStockholders | -156.81M | -117.81M | 47.42M | 194.24M |
| NetIncome | -156.81M | -117.81M | 47.42M | 194.24M |
| NetIncomeIncludingNoncontrollingInterests | -156.81M | -117.81M | 47.42M | 194.24M |
| NetIncomeDiscontinuousOperations | 25.81M | 57.11M | 229.45M | 385.78M |
| NetIncomeContinuousOperations | -182.63M | -174.92M | -182.03M | -191.55M |
| TaxProvision | 0.00 | 0.00 | ||
| PretaxIncome | -182.63M | -174.92M | -182.03M | -191.55M |
| OtherIncomeExpense | 4.11M | 1.74M | ||
| OtherNonOperatingIncomeExpenses | 1.74M | |||
| SpecialIncomeCharges | 0.00 | 4.11M | 0.00 | 0.00 |
| OtherSpecialCharges | -4.11M | |||
| NetNonOperatingInterestIncomeExpense | -13.37M | -14.50M | -18.64M | -17.93M |
| InterestExpenseNonOperating | 24.68M | 30.84M | 22.70M | 19.67M |
| InterestIncomeNonOperating | 11.30M | 16.34M | 4.06M | 1.74M |
| OperatingIncome | -169.26M | -164.53M | -163.39M | -173.62M |
| OperatingExpense | 169.26M | 164.53M | 163.39M | 173.62M |
| ResearchAndDevelopment | 119.52M | 114.87M | 112.72M | 118.78M |
| SellingGeneralAndAdministration | 49.73M | 49.66M | 50.67M | 54.84M |
| GeneralAndAdministrativeExpense | 49.73M | 49.66M | 50.67M | 54.84M |
| OtherGandA | 43.38M | 42.52M | 42.63M | 46.69M |
| SalariesAndWages | 6.36M | 7.14M | 8.04M | 8.15M |
| GrossProfit | 0.00 | |||
| CostOfRevenue | 0.00 | |||
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 58.04M | 61.13M | 62.83M | 62.63M |
| ShareIssued | 58.04M | 61.13M | 62.83M | 62.63M |
| NetDebt | 184.18M | 206.05M | 304.28M | 212.65M |
| TotalDebt | 207.02M | 236.46M | 342.02M | 347.84M |
| TangibleBookValue | -182.61M | -24.98M | 85.68M | 23.78M |
| InvestedCapital | 4.97M | 188.17M | 400.97M | 337.24M |
| WorkingCapital | 54.59M | 164.58M | 306.85M | 196.17M |
| NetTangibleAssets | -182.61M | -24.98M | 85.68M | 23.78M |
| CapitalLeaseObligations | 19.44M | 23.30M | 26.74M | 34.38M |
| CommonStockEquity | -182.61M | -24.98M | 85.68M | 23.78M |
| TotalCapitalization | -16.03M | 188.17M | 306.59M | 337.24M |
| TotalEquityGrossMinorityInterest | -182.61M | -24.98M | 85.68M | 23.78M |
| StockholdersEquity | -182.61M | -24.98M | 85.68M | 23.78M |
| RetainedEarnings | -910.35M | -753.53M | -635.72M | -683.13M |
| AdditionalPaidInCapital | 727.16M | 727.94M | 720.77M | 706.29M |
| CapitalStock | 580.00K | 611.00K | 628.00K | 626.00K |
| CommonStock | 580.00K | 611.00K | 628.00K | 626.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 459.69M | 403.25M | 505.29M | 395.49M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 380.16M | 349.94M | 368.90M | 343.70M |
| OtherNonCurrentLiabilities | 195.61M | 116.55M | 125.13M | |
| NonCurrentAccruedExpenses | 4.50M | 2.09M | 444.00K | 1.11M |
| LongTermDebtAndCapitalLeaseObligation | 180.05M | 231.30M | 243.33M | 342.58M |
| LongTermCapitalLeaseObligation | 13.47M | 18.14M | 22.43M | 29.13M |
| LongTermDebt | 166.58M | 213.16M | 220.91M | 313.46M |
| CurrentLiabilities | 79.53M | 53.32M | 136.38M | 51.79M |
| OtherCurrentLiabilities | 20.64M | 8.58M | 1.15M | |
| CurrentDebtAndCapitalLeaseObligation | 26.97M | 5.16M | 98.69M | 5.25M |
| CurrentCapitalLeaseObligation | 5.97M | 5.16M | 4.31M | 5.25M |
| CurrentDebt | 21.00M | 94.38M | ||
| OtherCurrentBorrowings | 21.00M | 94.38M | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 8.87M | 7.38M | 6.67M | 3.71M |
| PayablesAndAccruedExpenses | 23.04M | 32.20M | 29.88M | 42.83M |
| CurrentAccruedExpenses | 17.14M | 24.49M | 23.89M | 29.09M |
| InterestPayable | 2.67M | 4.24M | 5.17M | 5.17M |
| Payables | 5.91M | 7.71M | 5.99M | 13.74M |
| TotalTaxPayable | 4.87M | 338.00K | ||
| IncomeTaxPayable | 4.87M | 338.00K | ||
| AccountsPayable | 5.91M | 7.71M | 5.99M | 13.40M |
| TotalAssets | 277.08M | 378.27M | 590.97M | 419.27M |
| TotalNonCurrentAssets | 142.96M | 160.37M | 147.73M | 171.31M |
| OtherNonCurrentAssets | 1.05M | 1.05M | 1.05M | 1.05M |
| NonCurrentPrepaidAssets | 67.00K | |||
| NonCurrentAccountsReceivable | 124.27M | 138.74M | 123.42M | 140.25M |
| NetPPE | 17.64M | 20.58M | 23.25M | 30.01M |
| AccumulatedDepreciation | -11.07M | -10.24M | -9.55M | -9.03M |
| GrossPPE | 28.71M | 30.82M | 32.80M | 39.04M |
| OtherProperties | 26.97M | 29.09M | 31.10M | 37.35M |
| MachineryFurnitureEquipment | 1.74M | 1.74M | 1.70M | 1.69M |
| BuildingsAndImprovements | 14.96M | 18.63M | 21.76M | 28.28M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 134.12M | 217.90M | 443.24M | 247.96M |
| OtherCurrentAssets | 7.17M | 8.58M | 6.30M | 8.22M |
| PrepaidAssets | 8.15M | |||
| Receivables | 36.82M | 37.47M | 242.02M | 82.47M |
| OtherReceivables | 29.88M | 30.75M | 29.05M | 47.00M |
| AccountsReceivable | 6.94M | 6.72M | 212.97M | 35.47M |
| CashCashEquivalentsAndShortTermInvestments | 90.13M | 171.85M | 194.92M | 157.27M |
| OtherShortTermInvestments | 86.73M | 164.74M | 183.91M | 56.46M |
| CashAndCashEquivalents | 3.40M | 7.11M | 11.01M | 100.81M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -148.97M | 74.30M | -86.60M | -110.00M |
| RepurchaseOfCapitalStock | -11.85M | -4.65M | 0.00 | 0.00 |
| RepaymentOfDebt | -41.34M | -101.58M | -1.17M | -1.82M |
| IssuanceOfDebt | 0.00 | 0.00 | ||
| IssuanceOfCapitalStock | 0.00 | 0.00 | ||
| CapitalExpenditure | -165.00K | -426.00K | -113.00K | -277.00K |
| InterestPaidSupplementalData | 35.69M | 29.92M | 19.18M | 17.88M |
| IncomeTaxPaidSupplementalData | 165.00K | 3.29M | 80.00K | |
| EndCashPosition | 3.40M | 7.11M | 11.01M | 100.81M |
| BeginningCashPosition | 7.11M | 11.01M | 100.81M | 10.50M |
| ChangesInCash | -3.71M | -3.90M | -89.80M | 90.31M |
| FinancingCashFlow | 62.88M | -106.08M | 124.25M | 6.32M |
| CashFlowFromContinuingFinancingActivities | 62.88M | -106.08M | 124.25M | 6.32M |
| NetOtherFinancingCharges | 115.53M | 125.00M | -241.00K | |
| ProceedsFromStockOptionExercised | 547.00K | 150.00K | 415.00K | 8.38M |
| NetCommonStockIssuance | -11.85M | -4.65M | 0.00 | 0.00 |
| CommonStockPayments | -11.85M | -4.65M | 0.00 | 0.00 |
| CommonStockIssuance | 0.00 | 0.00 | ||
| NetIssuancePaymentsOfDebt | -41.34M | -101.58M | -1.17M | -1.82M |
| NetLongTermDebtIssuance | -41.34M | -101.58M | -1.17M | -1.82M |
| LongTermDebtPayments | -41.34M | -101.58M | -1.17M | -1.82M |
| LongTermDebtIssuance | 0.00 | 0.00 | ||
| InvestingCashFlow | 82.22M | 27.45M | -127.56M | 193.71M |
| CashFlowFromContinuingInvestingActivities | 82.22M | 27.45M | -127.56M | 193.71M |
| NetInvestmentPurchaseAndSale | 82.38M | 27.88M | -127.45M | 67.99M |
| SaleOfInvestment | 1.07B | 1.05B | 301.59M | 100.00M |
| PurchaseOfInvestment | -987.38M | -1.02B | -429.05M | -32.01M |
| NetBusinessPurchaseAndSale | 0.00 | 0.00 | 125.99M | |
| SaleOfBusiness | 0.00 | 0.00 | 125.99M | |
| NetPPEPurchaseAndSale | -165.00K | -426.00K | -113.00K | -277.00K |
| PurchaseOfPPE | -165.00K | -426.00K | -113.00K | -277.00K |
| OperatingCashFlow | -148.80M | 74.73M | -86.48M | -109.72M |
| CashFlowFromContinuingOperatingActivities | -148.80M | 74.73M | -86.48M | -109.72M |
| ChangeInWorkingCapital | 29.74M | 247.42M | -119.36M | -14.11M |
| ChangeInOtherWorkingCapital | 668.00K | |||
| ChangeInPayablesAndAccruedExpense | -10.78M | 4.68M | -10.66M | 14.64M |
| ChangeInPayable | 14.64M | |||
| ChangeInAccountPayable | 14.64M | |||
| ChangeInPrepaidAssets | 517.00K | -2.98M | 934.00K | 5.57M |
| ChangeInReceivables | 40.01M | 245.72M | -109.63M | -34.31M |
| ChangesInAccountReceivables | 357.00K | 205.12M | -175.07M | -34.31M |
| OtherNonCashItems | -28.80M | -54.63M | -29.57M | 1.70M |
| StockBasedCompensation | 10.49M | 11.65M | 14.07M | 17.63M |
| AmortizationOfSecurities | -4.37M | -8.71M | 0.00 | 0.00 |
| DeferredTax | 0.00 | 0.00 | ||
| DeferredIncomeTax | 0.00 | 0.00 | ||
| DepreciationAmortizationDepletion | 950.00K | 920.00K | 952.00K | 1.39M |
| DepreciationAndAmortization | 950.00K | 920.00K | 952.00K | 1.39M |
| OperatingGainsLosses | -4.11M | -310.56M | ||
| GainLossOnSaleOfBusiness | 0.00 | 0.00 | -310.56M | |
| NetIncomeFromContinuingOperations | -156.81M | -117.81M | 47.42M | 194.24M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for OMER
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|